RxDoctor Payments Data

Grant Craig, MD

Family Medicine · Sherman, TXNPI 1598809741

Payments from drug & device makers

$12,913in general payments, 2019–2025

Across 928 payments — averaging $13.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$835
  • GSK$809
  • Merck$631
  • Lilly USA, LLC$614
  • Amgen$607
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$12,81599%
  • Education$981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)273$2,641
Pfizer57$835
GSK57$809
Merck40$631
Lilly USA, LLC51$614
Amgen37$607
Bayer32$578
AstraZeneca29$516
Novo Nordisk38$513
Supernus Pharmaceuticals, Inc.67$325
Medicure Pharma Inc.3$318
Novartis19$311
Astellas Pharma US Inc14$307
Corcept Therapeutics16$303
Idorsia Pharmaceuticals US Inc13$272
Johnson & Johnson15$267
Otsuka America Pharmaceutical, Inc.12$257
Boehringer Ingelheim13$247
Abbott11$191
Amarin Pharma, Inc.9$157
Dexcom, Inc.8$148
Eisai Inc.7$129
Teva Pharmaceuticals USA, Inc.6$123
Bausch Health US, LLC6$116
Medtronic4$113
Sanofi-aventis U.S. LLC6$88
Azurity Pharmaceuticals, Inc.6$87
Takeda Pharmaceuticals U.S.A., Inc.6$84
Antares Pharma, Inc.5$79
Esperion Therapeutics, Inc.4$76
Phathom Pharmaceuticals, Inc.5$69
Axsome Therapeutics, Inc.4$69
Bristol Myers Squibb5$68
Cequr Corporation1$65
Biohaven Pharmaceuticals, Inc.4$64
Assertio Therapeutics, Inc.4$63
Si-bone, Inc.2$54
Heartflow, Inc.2$52
Shire North American Group Inc4$52
Biohaven Pharmaceutical Holding Company Ltd.3$48
Kowa Pharmaceuticals America, Inc.3$47
Optinose US, Inc.2$45
Boston Scientific2$43
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$41
Sequel Med Tech, LLC2$40
Nestle Healthcare Nutrition Inc.2$40
Ascensia Diabetes Care US Inc.2$39
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$38
Sunovion Pharmaceuticals Inc.2$33
Arbor Pharmaceuticals, Inc.2$30
Insulet Corporation1$28
Neuronetics, Inc.1$24
Genentech USA, Inc.2$24
Lundbeck LLC1$23
Promius Pharma LLC1$20
Alnylam Pharmaceuticals Inc.1$19
Almatica Pharma LLC1$16
Upsher-smith Laboratories LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,913 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$164,560
Medicare patients
432
Services billed
5,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide175$233,188
OzempicSemaglutide170$208,176
EliquisApixaban64$62,208
FarxigaDapagliflozin Propanediol46$43,273
LinzessLinaclotide39$37,362
Soliqua 100-33Insulin Glargine/Lixisenatide31$31,074
XareltoRivaroxaban25$22,701
JanuviaSitagliptin Phosphate12$18,597
Liothyronine Sodium436$13,906
Janumet XrSitagliptin Phos/Metformin Hcl13$12,280
Rosuvastatin Calcium723$10,924
JardianceEmpagliflozin11$10,683
MyrbetriqMirabegron16$10,403
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$9,985
Memantine Hcl157$9,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$614$233,188175 claims
Novo NordiskOzempic$513$208,176170 claims
PfizerEliquis$835$62,20864 claims
AstraZenecaFarxiga, Symbicort$516$46,12258 claims
AbbVieLinzess, Synthroid$2,641$41,380117 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$88$31,07431 claims
MerckJanuvia, Janumet Xr$631$30,87725 claims
Johnson & JohnsonXarelto$267$22,70125 claims
Boehringer IngelheimJardiance$247$10,68311 claims
Astellas Pharma US IncMyrbetriq$307$10,40316 claims
NovartisExelon$311$7,91111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →